2.14
-0.16(-6.96%)
Currency In USD
| Previous Close | 2.3 |
| Open | 2.32 |
| Day High | 2.36 |
| Day Low | 2.11 |
| 52-Week High | 2.37 |
| 52-Week Low | 0.65 |
| Volume | 558,255 |
| Average Volume | 362,677 |
| Market Cap | 128.2M |
| PE | -1.14 |
| EPS | -1.88 |
| Moving Average 50 Days | 1.68 |
| Moving Average 200 Days | 1.19 |
| Change | -0.16 |
If you invested $1000 in Opus Genetics, Inc. (IRD) since IPO date, it would be worth $26,750 as of November 04, 2025 at a share price of $2.14. Whereas If you bought $1000 worth of Opus Genetics, Inc. (IRD) shares 1 year ago, it would be worth $1,658.91 as of November 04, 2025 at a share price of $2.14.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness
GlobeNewswire Inc.
Yesterday at 1:00 PM GMT
RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs), announced today that its pione
Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference
GlobeNewswire Inc.
Oct 14, 2025 12:00 PM GMT
RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseas
Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025
GlobeNewswire Inc.
Oct 02, 2025 12:00 PM GMT
RESEARCH TRIANGLE PARK, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therap